急性脑出血术后危重症相关皮质类固醇不足:一项前瞻性队列联合氢化可的松随机试验(HYPER研究)
这项多中心研究结合前瞻性观察队列与单盲随机对照试验,纳入18–80岁急性脑出血(创伤性如硬膜外/硬膜下血肿,非创伤性如动脉瘤性蛛网膜下腔出血)行神经外科手术的患者,术后第2或3天行高剂量促肾上腺皮质激素刺激试验。497例筛选患者中255例术后患者接受检测,64例(25.1%)诊断为危重症相关皮质类固醇不足并1:1随机接受静脉氢化可的松或安慰剂。主要终点30天改良Rankin量表神经功能改善无显著差异,但氢化可的松显著缩短机械通气持续时间(中位5天 vs 10天,p=0.032)和ICU住院时间(中位5天 vs 13天,p=0.038),未增加严重不良事件。作者认为这些发现需进一步充分把握度的研究来评估皮质类固醇治疗在急性脑出血合并危重症相关皮质类固醇不足患者中的作用。
要点
- 急性脑出血术后患者危重症相关皮质类固醇不足发生率为25.1%(64/255),术后第2或3天以高剂量促肾上腺皮质激素刺激试验诊断。
- 独立预测因素包括创伤性硬膜下血肿、硬膜外血肿、机械通气和新鲜冰冻血浆输注。
- 氢化可的松未显著改善30天改良Rankin量表神经功能,但显著缩短机械通气持续时间(中位5天 vs 10天,p=0.032)和ICU住院时间(中位5天 vs 13天,p=0.038)。
- 氢化可的松组未观察到严重不良事件增加。
- 作者结论:靶向氢化可的松治疗改善短期ICU参数,但需进一步充分把握度的研究评估皮质类固醇治疗的作用。
适用人群与场景
- 18–80岁因急性脑出血在入院48小时内行神经外科手术的成人患者,入住三级医院。
- 急性脑出血经计算机断层扫描或磁共振成像确认,包括创伤性(如硬膜外或硬膜下血肿)和非创伤性(如动脉瘤性蛛网膜下腔出血)病因。
诊断标准与关键阈值
- 危重症相关皮质类固醇不足诊断:术后第2或3天行高剂量促肾上腺皮质激素刺激试验。
处置流程与药物剂量
- 术后第2或3天行高剂量促肾上腺皮质激素刺激试验筛查危重症相关皮质类固醇不足。
- 确诊危重症相关皮质类固醇不足的患者按1:1随机接受静脉氢化可的松或安慰剂;原文未写明氢化可的松剂量、给药频次和疗程。
研究设计与关键结果
- 多中心研究,结合前瞻性观察队列与单盲随机对照试验;497例筛选,255例术后患者接受肾上腺功能检测,64例(25.1%)诊断危重症相关皮质类固醇不足并随机。
- 危重症相关皮质类固醇不足独立预测因素:创伤性硬膜下血肿、硬膜外血肿、机械通气、新鲜冰冻血浆输注。
- 主要终点30天改良Rankin量表神经功能改善:氢化可的松组与安慰剂组无显著差异。
- 机械通气持续时间:氢化可的松组中位5天(IQR 3–7) vs 安慰剂组中位10天(IQR 6–16),p=0.032。
- ICU住院时间:氢化可的松组中位5天(IQR 2–13) vs 安慰剂组中位13天(IQR 3–18),p=0.038。
- 严重不良事件:氢化可的松组未增加。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察队列联合单盲随机对照试验。
- 局限:作者指出这些发现需进一步充分把握度的研究来评估皮质类固醇治疗在急性脑出血合并危重症相关皮质类固醇不足患者中的作用。
对床旁实践的改变
- 对急性脑出血术后患者,可考虑术后第2或3天行高剂量促肾上腺皮质激素刺激试验筛查危重症相关皮质类固醇不足,尤其存在创伤性硬膜下血肿、硬膜外血肿、机械通气或新鲜冰冻血浆输注者。
- 对确诊危重症相关皮质类固醇不足的患者,静脉氢化可的松可能缩短机械通气持续时间和ICU住院时间,但未显著改善30天神经功能;作者认为需进一步充分把握度的研究评估其作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Critical illness-related corticosteroid insufficiency (CIRCI) is a potentially underrecognized complication in postoperative patients with acute brain hemorrhage. Its incidence, associated risk factors, and the therapeutic role of corticosteroids in this population remain unclear. METHOD: This multicenter study combined a prospective observational cohort with a single-blinded randomized controlled trial. Adult patients aged 18–80 years who underwent neurological surgery for acute brain hemorrhage within 48 h of admission at tertiary care hospitals were eligible for inclusion. Acute brain hemorrhage was confirmed by computed tomography or magnetic resonance imaging and included both traumatic (e.g., epidural or subdural hematoma) and non-traumatic etiologies (e.g., aneurysmal subarachnoid hemorrhage). Among 497 screened patients, 255 eligible postoperative patients underwent adrenal function testing using a high-dose corticotropin stimulation test (HDST) on postoperative day (POD) 2 or 3. Patients diagnosed with CIRCI (n = 64, 25.1%) were randomized in a 1:1 ratio to receive intravenous hydrocortisone or placebo. The primary outcome was neurological improvement at 30 days assessed using the modified Rankin Scale (mRS). RESULTS: CIRCI was diagnosed in 25.1% of patients. Independent predictors of CIRCI included traumatic subdural hematoma, epidural hematoma, mechanical ventilation, and fresh frozen plasma transfusion. While hydrocortisone did not significantly improve the primary outcome of 30-day neurological function, it significantly reduced mechanical ventilation duration (median [IQR], 5 [3–7] vs. 10 [6–16] days; p = 0.032) and ICU length of stay (5 [2–13] vs. 13 [3–18] days; p = 0.038). No increase in serious adverse events was observed. CONCLUSION: CIRCI is common in postoperative patients with acute brain hemorrhage and is associated with specific clinical risk factors. Although targeted hydrocortisone therapy did not significantly improve functional outcomes at 30 days, it yielded significant improvements in short-term ICU parameters. These findings warrant further adequately powered studies to evaluate the role of corticosteroid therapy in patients with acute brain hemorrhage diagnosed with CIRCI. CLINICAL TRIAL REGISTRATION: This study was registered with the Clinical Research Information Service (CRIS), a primary registry of the WHO International Clinical Trials Registry Platform, under the identifier KCT0004425. The trial was prospectively registered on 5 November 2019.
参考来源
- Kim M, Jung H, Kim SB, et al. Critical illness-related corticosteroid insufficiency after acute brain hemorrhage surgery: a prospective cohort study with a randomized trial of hydrocortisone : HYdrocortisone theraPy in nEurocRitical illness; HYPER study. Crit Care. 2026. PMID: 41731600. doi:10.1186/s13054-026-05915-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。